Skip to main content
logo
Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
0.7621
-0.0207 (-2.64%)
At close: Aug 28, 2026, 4:00 PM EDT
0.7700
+0.0079 (1.04%)
After-hours: Aug 28, 2026, 6:28 PM EDT

Rein Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Cost of Revenue
-----------------8.17---
Gross Profit
----------------8.17---
Selling, General & Admin
10.3610.510.911.429.9612.6813.8616.7216.3312.9211.368.338.629.339.689.639.99.459.69.61
Research & Development
10.3911.0511.0312.3514.3913.8414.2512.99.25.643.994.428.6413.8817.9720.1328.3318.5917.0114.37
Operating Expenses
20.7621.5521.9323.7724.3526.5228.1129.6225.5218.5615.3512.7517.2523.2227.6529.7638.2428.0426.6123.98
Operating Income
-20.76-21.55-21.93-23.77-24.35-26.52-28.11-29.62-25.52-18.56-15.35-12.75-17.25-23.22-27.65-29.76-30.07-28.04-26.61-23.98
Interest Expense
------------0.18-0.07-0.02------0.02
Interest & Investment Income
---0.70.70.70.70.60.60.60.6----0.130.040.01--
Other Non Operating Income (Expenses)
-1.02-0.670.05-0.36-0.050-0.02-0.25-0.34-0.23-0.090.90.780.570.320.050.05-0.03-0.01-0.01
EBT Excluding Unusual Items
-21.77-22.22-21.88-23.43-23.7-25.82-27.43-29.26-25.26-18.2-14.84-12.03-16.55-22.66-27.33-29.58-29.98-28.06-26.62-24.01
Merger & Restructuring Charges
-------0.010.010.09-0.93-0.94-0.93-1.02------
Gain (Loss) on Sale of Assets
-------0.010.040.040.040.03----0.070.070.070.09
Asset Writedown
-28.7-28.7-28.7-37-37-37-37-------------
Other Unusual Items
-----------------0.390.39-0.44
Pretax Income
-50.47-50.92-50.58-60.43-60.7-62.82-64.43-29.24-25.22-18.07-15.73-12.94-17.48-23.69-27.33-29.58-29.92-27.61-26.16-24.36
Income Tax Expense
-0.71-0.71-0.71-1.54-1.54-1.54-1.54-------------
Net Income
-49.76-50.21-49.87-58.89-59.15-61.27-62.88-29.24-25.22-18.07-15.73-12.94-17.48-23.69-27.33-29.58-29.92-27.61-26.16-24.36
Net Income to Common
-49.76-50.21-49.87-58.89-59.15-61.27-62.88-29.24-25.22-18.07-15.73-12.94-17.48-23.69-27.33-29.58-29.92-27.61-26.16-24.36
Net Income Growth (YoY)
--------------------
Shares Outstanding (Basic)
3828252422211814965555555544
Shares Outstanding (Diluted)
3828252422211814965555555544
Shares Change (YoY)
71.24%29.11%41.84%71.80%137.74%285.32%290.09%201.87%107.31%21.97%1.31%0.10%0.12%0.21%2.23%18.73%42.67%85.87%154.70%142.08%
EPS (Basic)
-1.30-1.82-1.96-2.50-2.64-2.87-3.51-2.13-2.68-3.26-3.42-2.85-3.85-5.22-6.02-6.52-6.60-6.09-5.89-6.38
EPS (Diluted)
-1.30-1.82-1.96-2.50-2.64-2.87-3.51-2.13-2.68-3.26-3.42-2.85-3.85-5.22-6.02-6.52-6.60-6.10-5.89-6.38
EPS Growth (YoY)
--------------------

Additional Metrics

Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Free Cash Flow
-18.83-16.61-19.36-20.95-21.22-23.2-22.29-27.87-25.69-20.42-19.81-13.83-19.16-21.73-24.87-26.71-27.01-25.15-23.91-22.35
Free Cash Flow Per Share
-0.49-0.60-0.76-0.89-0.95-1.09-1.24-2.03-2.73-3.69-4.31-3.04-4.22-4.78-5.48-5.89-5.95-5.55-5.38-5.85
EBITDA
-20.76-21.57-21.93-23.77-24.35-26.5-28.05-29.5-25.4-18.43-15.23-12.64-17.11-23.04-27.48-29.59-29.91-27.88-26.48-23.89
D&A For EBITDA
0-0.010000.020.060.120.130.140.120.110.140.170.170.170.160.160.120.09
EBIT
-20.76-21.55-21.93-23.77-24.35-26.52-28.11-29.62-25.52-18.56-15.35-12.75-17.25-23.22-27.65-29.76-30.07-28.04-26.61-23.98
SEC Filings: 10-K · 10-Q